Liteng Shen
Overview
Explore the profile of Liteng Shen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bian Q, Shen Z, Gao J, Shen L, Lu Y, Zhang Q, et al.
J Chem Inf Model
. 2025 Jan;
65(2):461-471.
PMID: 39761551
Predicting protein-protein interactions (PPIs) is crucial for advancing drug discovery. Despite the proposal of numerous advanced computational methods, these approaches often suffer from poor usability for biologists and lack generalization....
2.
Yu Q, Gao L, Xu L, Han Y, Cao Y, Xi J, et al.
Bioorg Med Chem
. 2024 Nov;
115:117983.
PMID: 39500271
Under hypoxic conditions, the accumulation of misfolded proteins primarily relies on the autonomous activity of 20S proteasome for degradation. The buildup of toxic proteins in cardiomyocyte contribute to various cardiovascular...
3.
Zhang J, Duan H, Gui R, Wu M, Shen L, Jin Y, et al.
Eur J Med Chem
. 2024 Nov;
262:115872.
PMID: 39491427
BRD9 is essential in regulating gene transcription and chromatin remodeling, and blocking BRD9 profoundly affects the survival of AML cells. However, the inhibitors of BRD9 suffer from various drawbacks, including...
4.
Gao J, Shen Z, Lu Y, Shen L, Zhou B, Xu D, et al.
J Chem Inf Model
. 2024 Sep;
64(19):7337-7348.
PMID: 39323109
Molecular property prediction (MPP) techniques are pivotal in reducing drug development costs by preemptively predicting bioactivity and ADMET properties. Despite the application of numerous deep learning approaches, enhancing the representational...
5.
Yang J, He Y, Kang Y, Shen L, Zhang W, Yan Y, et al.
ACS Med Chem Lett
. 2024 Sep;
15(9):1491-1499.
PMID: 39291017
Methyltransferase-like 3 (METTL3) is an RNA methyltransferase that catalyzes the -methyladenosine (m6A) modification of mRNA in eukaryotic cells. Past studies have shown that METTL3 is highly expressed in various cancers...
6.
Lu Y, Shen Z, Xu Y, Lin H, Shen L, Jin Y, et al.
J Med Chem
. 2024 Jul;
67(14):11712-11731.
PMID: 38996382
Ferroptosis is a promising therapeutic target for injury-related diseases, yet diversity in ferroptosis inhibitors remains limited. In this study, initial structure optimization led us to focus on the bond dissociation...
7.
Duan H, Zhang J, Gui R, Lu Y, Pang A, Chen B, et al.
J Med Chem
. 2024 Jun;
67(13):11326-11353.
PMID: 38913763
BRD9 is a pivotal epigenetic factor involved in cancers and inflammatory diseases. Still, the limited selectivity and poor phenotypic activity of targeted agents make it an atypically undruggable target. PROTAC...
8.
Guo Y, Shen Z, Zhao W, Lu J, Song Y, Shen L, et al.
Adv Sci (Weinh)
. 2024 Jan;
11(13):e2306309.
PMID: 38269648
Bystander-killing payloads can significantly overcome the tumor heterogeneity issue and enhance the clinical potential of antibody-drug conjugates (ADC), but the rational design and identification of effective bystander warheads constrain the...
9.
Chen X, Zhao J, Chen R, Shen L, Lu J, Guo Y, et al.
Arch Pharm (Weinheim)
. 2024 Jan;
357(4):e2300516.
PMID: 38263717
PIM2, part of the PIM kinase family along with PIM1 and PIM3, is often overexpressed in hematologic cancers, fueling tumor growth. Despite its significance, there are no approved drugs targeting...
10.
Jin T, Xu W, Chen R, Shen L, Gao J, Xu L, et al.
Front Pharmacol
. 2023 Dec;
14:1298245.
PMID: 38143493
G/M cell cycle checkpoint protein WEE1 kinase is a promising target for inhibiting tumor growth. Although various WEE1 inhibitors have entered clinical investigations, their therapeutic efficacy and safety profile remain...